Compare Citius Pharmaceuticals Inc (CTXR) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs State Street PDR S&P Retail ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while State Street PDR S&P Retail ETF trades at $89.79. The key difference: State Street PDR S&P Retail ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | XRT | |
|---|---|---|
Market Cap | $18.73M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $92.35 |
52-Week Low | $0.48 | $77.28 |
Enterprise Value | $14.95M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
XRT trades at $90.82, up 1.08% with a bullish technical signal supported by moving averages. The ETF shows neutral oscillators like RSI at 57.83, while ADX indicates a strong trend. Support lies at $90 and resistance at $91. Recent retail sales growth and positive economic data provide a favorable backdrop, though sentiment is mixed amid inflation concerns.
Outlook is cautiously optimistic with retail sector momentum, but risks include consumer sentiment pressures and valuation headwinds. The ETF's diversification offers stability, yet macroeconomic shifts could impact performance. Investors should weigh technical strength against fundamental uncertainties in the retail space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
